Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with
cABSSSI (major cutaneous abscesses) due to MRSA.
Secondary Objective(s):
- To assess the pharmacokinetics of CG400549 (960 mg daily) in subjects with cABSSSI due
to MRSA
- To explore the in vitro susceptibility of cABSSSI-related bacteria to CG400549.
- To assess the safety of multiple doses of CG400459